Skip to main content
Evidence Based Longevity (EBL)Check what I take
← All protocols

Protocol · not graded

Fermented foods (yogurt, kefir, kimchi and similar) for inflammation

In a 17-week randomized study of 18 people per arm, a diet high in fermented foods increased gut microbiome diversity and lowered inflammatory markers, while the trial's primary outcome was unchanged.

At a glance

In plain words

One small study had people eat several servings a day of fermented foods such as yogurt, kefir and kimchi for about four months. Their gut bacteria became more varied and some markers of inflammation fell. The study was small, and its main measure did not change.

The letter, taken apart
What was measured
Gut microbiome diversity and immune markers over 17 weeks.
How big
Microbiome diversity rose and inflammatory markers fell; the primary outcome was unchanged.Read from the summary of PMID PubMed ID: the permanent number the US National Library of Medicine gives a published paper. Each one links to that paper's record on PubMed. 34256014.
Who it applies to
Healthy adults, 18 per arm.
Safety
None identified.
The record in one view
Compared with
Each person's own baseline (and a high-fiber diet arm).
Certainty
No letter yet: the trials so far do not meet the bar for one.
What would change this grade
Could rise to C with: Randomized trial of a high-fermented-food diet against a matched control diet. Who: Adults. Measured: A clinical outcome or an established stand-in. Length: At least 6 months.
Cost
No price recorded yet.
Sources
2 studies cited on this record, listed under Sources.
For clinicians
A one-page summary of this record that prints with a clinician's name and practice, folds to a plain-language patient handout, and gives a chart note to paste into the patient record: Printable summary and chart note.
Food
Not graded

In a 17-week randomized study of 18 people per arm, a diet high in fermented foods increased gut microbiome diversity and lowered inflammatory markers, while the trial's primary outcome was unchanged. With 18 people per arm and each diet compared with its own baseline, this is a pilot, and EBL does not grade it.

Why no letter

Who responds: this record's trial reading reports no subgroup that identifies who responds.

Why this carries no letter

Not graded. One 17-week randomized study of 18 people per arm found lower inflammatory markers on a high-fermented-food diet, but its primary outcome (cytokine response score) was unchanged, inflammatory markers are not established stand-ins, and each diet was compared with its own baseline rather than with a control diet. A 2026 crossover A trial design in which each participant receives both the treatment and the comparison, one after the other, and serves as their own control. trial of sauerkraut in 87 people also compared each phase with its own baseline and had no control food.

Evidence notes: randomized trial, pilot study

Last reviewed: November 2026

Evidence wanted

The trial that would change this grade.

DesignRandomized trial of a high-fermented-food diet against a matched control diet
PopulationAdults
Endpoint The outcome a trial measures to decide whether the treatment worked, such as heart attacks, blood pressure or a symptom score.A clinical outcome or an established stand-in
DurationAt least 6 months

A positive trial of this shape would move this entry to C.

Why the current trials fall short

A larger controlled trial is needed before any letter.

Dose, form and timing

What to track

None graded.

Safety

Safety evidence, by strength

No safety data. Each caution on this record, sorted by what it rests on.

Documented in human studies
Cautions resting on what randomized trials or large studies found in people.

None recorded.

Suspected from case reports
Harms reported in individual patients or uncontrolled observations, not confirmed by a trial.

None recorded.

Mechanistic only
Cautions reasoned from how it works, with no human harm data behind them.

None recorded.

Population cautions
Groups in whom it has not been studied, so its safety there is unknown.

None recorded.

No safety data

No safety data: EBL has found no trial or report of harm for this record. That is an absence of evidence, not a finding of safety.

Grade history

How this letter has changedLatest: No. 450 · November 2026 · First graded.
Grade history
No. 450 · November 2026 · First graded
Fermented foods (yogurt, kefir, kimchi and similar) for inflammation enters the food section: not graded

New record in the food section. In a 17-week randomized study of 18 people per arm, a diet high in fermented foods increased gut microbiome diversity and lowered inflammatory markers, while the trial's primary outcome was unchanged. With 18 people per arm and each diet compared with its own baseline, this is a pilot, and EBL does not grade it.PMID 34256014 PMID 42321414

Every change to a letter on this site is dated and published. The full evidence log →

Sources

The evidence, in fullTwo papers, each linked to its PubMed record.
The evidence

Wastyk et al. (Cell, 2021; PMID 34256014): 17-week randomized prospective study, 18 healthy adults per arm, high-fiber or high-fermented-food diet; cytokine response score (primary outcome) unchanged; the fermented-food diet steadily increased microbiota diversity and decreased inflammatory markers. Schropp et al. (Eur J Clin Nutr, 2026; PMID 42321414): randomized crossover trial, 87 healthy adults, 100 g a day of fresh or pasteurized sauerkraut for 4 weeks each; both were followed by a small fall in systolic blood pressure from baseline; no change in gut barrier markers; each phase was compared with its own baseline, with no non-fermented control.

How EBL searched for the trials (1 search)

The search that was run, what it returned, and what was left out and why, so the absence of evidence can be checked as well as its presence.

Searched PubMed in November 2026. 21 records screened, 2 eligible for the graded claim.
Query: ("fermented food*"[tiab]) AND (inflammat*[tiab] OR microbio*[tiab]) AND randomized controlled trial[pt]
All 21 records screened by title. The 2026 sauerkraut crossover trial (PMID 42321414) is on the record; others test single products or probiotics.
PubMed watch: new studies on this record (nothing new)

No new paper matching the search behind this record has been added to PubMed since November 2026.

Last run November 2026. A letter on EBL moves only after a logged review. A new paper never moves a letter by arriving: it is read, the answer is written here, and any change to the letter is published in the evidence log.

Disclosure

Educational use only · Not medical advice · EBL grades published human evidence and does not recommend treatment.

Evidence Based Longevity, Inc. is owner-operated and edited by Arnold Sandlow, D.C., a California-licensed chiropractor. Evidence Based Longevity publishes in English only · Machine translations are not produced or reviewed by EBL for accuracy

© Evidence Based Longevity, Inc. All rights reserved

Medical disclaimer

These statements have not been evaluated by the Food and Drug Administration. Any grade on this page describes the strength of published human trial evidence in the populations studied. It is not a recommendation for any individual and is not medical advice. Starting, stopping or changing any supplement or medication is a decision for your physician.

Grades move when new trials publish. A free monthly email lists every grade EBL moved, with the reason and the trial behind it: the sign-up is on the Evidence Log →

Build 9b19d78, November 2026